Detalhe da pesquisa
1.
Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinoma.
NPJ Precis Oncol
; 8(1): 82, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561473
2.
Loss of the DNA Repair Gene RNase H2 Identifies a Unique Subset of DDR-Deficient Leiomyosarcomas.
Mol Cancer Ther
; 2024 Apr 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38561019
3.
Detection of Biallelic Loss of DNA Repair Genes in Formalin-Fixed, Paraffin-Embedded Tumor Samples Using a Novel Tumor-Only Sequencing Panel.
J Mol Diagn
; 25(5): 295-310, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36944408
4.
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Nat Med
; 29(6): 1400-1411, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277454
5.
Guiding ATR and PARP inhibitor combinationswith chemogenomic screens.
Cell Rep
; 40(2): 111081, 2022 07 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35830811
6.
ATM Germline-Mutated Gastroesophageal Junction Adenocarcinomas: Clinical Descriptors, Molecular Characteristics, and Potential Therapeutic Implications.
J Natl Cancer Inst
; 114(5): 761-770, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078243
7.
Covalent ERα Antagonist H3B-6545 Demonstrates Encouraging Preclinical Activity in Therapy-Resistant Breast Cancer.
Mol Cancer Ther
; 21(6): 890-902, 2022 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35642432
8.
RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors.
Mol Cancer Ther
; 21(2): 245-256, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34911817
9.
Recovery from liver disease in a Niemann-Pick type C mouse model.
J Lipid Res
; 51(8): 2372-83, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20418540
10.
In vivo antisense oligonucleotide reduction of NPC1 expression as a novel mouse model for Niemann Pick type C- associated liver disease.
Hepatology
; 47(5): 1504-12, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18438776
11.
Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come.
Cancer Res
; 79(8): 1740-1745, 2019 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30952631
12.
Dual targeting of IGF-1R and ErbB3 as a potential therapeutic regimen for ovarian cancer.
Sci Rep
; 9(1): 16832, 2019 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31728045
13.
Author Correction: Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
Nat Commun
; 10(1): 2527, 2019 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31164653
14.
Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer.
Clin Cancer Res
; 24(12): 2873-2885, 2018 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29549161
15.
Discovery of Selective Estrogen Receptor Covalent Antagonists for the Treatment of ERαWT and ERαMUT Breast Cancer.
Cancer Discov
; 8(9): 1176-1193, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29991605
16.
H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Cancer Res
; 77(24): 6999-7013, 2017 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29247039
17.
Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.
Nat Commun
; 8(1): 103, 2017 07 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28740126
18.
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Mol Cancer Ther
; 13(2): 410-25, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24282274
19.
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Clin Cancer Res
; 18(16): 4449-57, 2012 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22661537
20.
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma.
PLoS One
; 6(1): e15640, 2011 Jan 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-21253578